Illumina, Inc.
ILMN · Nasdaq
- $206.45
- $31.44B
- Open
- —
- —
- $202.82 - $208.93
- $88.00 - $231.81
- —
- —
- 2.06M
About Illumina, Inc.
Illumina sells genetic-sequencing systems and the consumables used with them, with demand spanning clinical sequencing and other sequencing applications. Its business model combines instrument placements, including the NovaSeq X platform, with recurring consumables revenue generated as customers run tests and research workflows. The supplied evidence does not provide a segment revenue breakdown or identify individual customer groups beyond clinical sequencing users. Illumina reported $4.3 billion of fiscal 2025 revenue and $0.8 billion of net income, compared with $4.4 billion of revenue and a $1.2 billion net loss in fiscal 2024.
Notable Price Movement
- Aug 3-7$187.968.36%
Illumina rose 5.20% over the period, from $192.98 to $203.01. The main catalyst was its July 30 second-quarter report, which beat earnings estimates by 6.50% and revenue estimates by 3.36%, prompting the company to raise its 2026 revenue and earnings outlook. Management cited clinical sequencing demand, elevated NovaSeq X placements and stronger consumables activity. The stock jumped from $194.82 to $205.09 and held essentially flat on July 31, before giving back most of that gain on August 3, when it fell to $198.16. It rebounded 2.45% on August 4, leaving the shares above their pre-earnings level.
